m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05202
 [1]
Non-coding RNA miR-130a-3p METTL14  lncRNA       miRNA   circRNA Direct Inhibition m6A modification AIFM2 AIFM2 METTL14 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target Ferroptosis suppressor protein 1 (AIFM2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-130a-3p microRNA View Details
Regulated Target Methyltransferase-like protein 14 (METTL14) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary Exosomal hsa-miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of Ferroptosis suppressor protein 1 (AIFM2)
Responsed Disease Esophageal cancer ICD-11: 2B70
 Disease Info 
Responsed Drug Cisplatin
 Drug Info 
In-vitro Model
 TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
In-vivo Model The KYSE-150 cells were subcutaneously inoculated on the right side at a dosage of 106 cells per mouse. After the tumor grew to approximately 50 mm3, mice were randomly divided into four groups (n = 6): Control, CisR-exo, Cis, and Cis + CisR-exo. Then, normal saline or cisplatin (20 mg/kg; twice a week) was intratumorally injected alone or combined with CisR-exos (10 μ g; once every two days).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B70: Esophageal cancer 15 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Pembrolizumab Approved [2]
External Link
TTD: D08ANZ
 Compound Name Nivolumab Approved [2]
External Link
TTD: D00GOV
 Compound Name Claudiximab Phase 3 [3]
Synonyms
IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
    Click to Show/Hide
External Link
TTD: D0B3ZC
 Compound Name Golnerminogene pradenovac Phase 3 [4]
Synonyms
TNFerade (TN)
    Click to Show/Hide
External Link
TTD: D03QBT
 Compound Name DKN-01 Phase 2 [5]
External Link
TTD: DMF73Z
 Compound Name Pegamotecan Phase 2 [6]
Synonyms
Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
    Click to Show/Hide
External Link
CID: 11297617
TTD: D0D4CX
 Compound Name APR-246 Phase 2 [2]
Synonyms
Eprenetapopt
    Click to Show/Hide
External Link
CID: 52918385
TTD: D03XTY
DrugBank: DB11684
 Compound Name Opdivo + Yervoy Phase 3 [2]
External Link
TTD: D02VYE
 Compound Name Anti-NY-ESO-1 CAR-T cells Phase 1/2 [7]
External Link
TTD: D0LJ2S
 Compound Name Anti-MUC1 CAR-T cells Phase 1/2 [8]
External Link
TTD: D09KWN
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [9]
External Link
TTD: D08QYW
 Compound Name PCA062 Phase 1 [2]
External Link
TTD: D09WSR
 Compound Name Cellspan esophageal implant Clinical trial [2]
External Link
TTD: D0SW1D
 Compound Name PKI166 Discontinued in Phase 2 [10]
Synonyms
PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, > 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol
    Click to Show/Hide
External Link
CID: 6918403
TTD: D07GFF
 Compound Name Ramorelix Discontinued in Phase 1 [11]
Synonyms
Hoe-013
    Click to Show/Hide
External Link
CID: 25077455
TTD: D0S6AQ
References
Ref 1 Exosomal miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of FSP1. Int Immunopharmacol. 2025 Jan 27;146:113804. doi: 10.1016/j.intimp.2024.113804. Epub 2024 Dec 16.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT01197885) Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer. U.S. National Institutes of Health.
Ref 4 ClinicalTrials.gov (NCT00051467) A Study of TNFerade Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 ClinicalTrials.gov (NCT00080002) Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
Ref 7 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 8 ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
Ref 9 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7642).
Ref 11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008630)